BIOPHYTIS (EPA:ALBPS) - Biophytis Identifies False Report Regarding COVA study

Transparency directive : regulatory news

13/04/2021 23:00

Press release

Biophytis Identifies False Report Regarding COVA study

Paris, France, Cambridge (Massachusetts, United States), April 13 2021, 11PM
CET - Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a
clinical-stage biotechnology company focused on the development of therapeutics
that are aimed at slowing the degenerative processes associated with aging and
improving functional outcomes for patients suffering from age-related diseases,
including severe respiratory failure in patients suffering from COVID-19, has
been made aware of a false report regarding the status of its COVA study of its
Sarconeos (BIO101) treatment in COVID-19 in Brazil. On April 12, 2021, an
article was released via WBOC unbeknownst to Biophytis. The press release was
misleading and released without Bipohytis' knowledge by unknown sources.

Biophytis did not write, release nor approve this press release, on the subject
of the COVA study in Brazil. Biophytis has reported this instance to the proper
authorities and WBOC. Biophytis disclaims any responsibility arising out of or
in connection with this press release.

The most recent news on the COVA trial is that the independent Data Monitoring
Committee (DMC) delivered a favorable opinion on the safety of Sarconeos
(BIO101) in patients infected with COVID-19, following the scheduled interim
analysis of the 50 participants from Part 1 of the study. This press release,
dated March 22, 2021, can be read here.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19. Sarconeos (BIO101), our leading drug
candidate, is a small molecule, administered orally, being developed as a
treatment for sarcopenia in a Phase 2 clinical trial in the United States and
Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3
study (COVA) for the treatment of severe respiratory manifestations of COVID-19
in Europe, Latin America, and the US. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy
(DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont/Chris Maggos
sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

BIOPHYTIS's latest news

29/04/2024 14:39

BIOPHYTIS (EPA:ALBPS) - Biophytis Identifies False Report Regarding COVA study

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories